Intermittent preventive therapy (IPTp) using sulphadoxine-pyrimethamine (SP) is a key component of malaria prevention strategy in pregnant women. A pregnant woman is required to receive at least 3 doses of SP during her pregnancy, with each dose being given at least 1 month apart, starting the first dose in the earliest second trimester of pregnancy. Therefore, a descriptive cross-sectional study was designed to assess the knowledge and uptake of IPTp-SP among pregnant women living in low malaria prevalent region. The questionnaires were used to collect data on sociodemographic characteristics, obstetric history, and knowledge scale while information about SP use was extracted from antenatal clinic cards. Overall, 389 pregnant women with a mean age (± standard deviation) of 29 years (5.3) participated in the study where majority of them (80.7%) were married. Majority of the study participants (77.1%) were in the third trimester of pregnancy and multigravida (42.9%). Of 389, 37 (9.5%), 288 (74%), and 64 (16.5%) were found to have low, moderate, and high level of knowledge about the use of IPTp-SP respectively. Of 300 pregnant women who were in the third trimester, 37 (12.3%) did not take SP at all while 109 (36.3%), 61 (20.3%), and 93 (31%) had taken a single, two doses, three, or more SP doses respectively. Although majority of pregnant women had moderate to high level of knowledge about the use of IPTp-SP, but only one third of pregnant women did take three or more IPTp-SP doses.

中文翻译：

---

坦桑尼亚达累斯萨拉姆孕妇的间歇性预防性治疗的采用：描述性横断面研究

使用磺胺多辛-乙胺嘧啶（SP）的间歇性预防疗法（IPTp）是孕妇疟疾预防策略的关键组成部分。孕妇在怀孕期间必须接受至少3剂SP，每剂至少间隔1个月，从怀孕最早的中期开始第一个剂量。因此，设计了一项描述性横断面研究，以评估生活在低疟疾流行地区的孕妇中IPTp-SP的知识和摄取情况。问卷用于收集有关社会人口统计学特征，产科史和知识规模的数据，而有关SP使用的信息则是从产前诊所卡中提取的。总体而言，有389名平均年龄（±标准差）为29岁（5.3）的孕妇参加了该研究，其中大多数人（80。7％）已婚。大部分研究参与者（77.1％）处于妊娠中期和多胎妊娠（42.9％）。在389名中，分别有37（9.5％），288（74％）和64（16.5％）名人士对IPTp-SP的使用掌握了低，中和高水平的知识。在妊娠中期的300名孕妇中，有37名（12.3％）完全没有服用SP，而109名（36.3％），61名（20.3％）和93名（31％）分别服用了两剂，三剂，或分别使用更多SP剂量。尽管大多数孕妇对IPTp-SP的使用具有中等至高水平的了解，但只有三分之一的孕妇确实服用了三剂或更多剂IPTp-SP。和有关IPTp-SP使用的高水平知识。在妊娠晚期的300名孕妇中，有37名（12.3％）完全没有服用SP，而109名（36.3％），61名（20.3％）和93名（31％）分别服用了两剂，三剂，或分别使用更多SP剂量。尽管大多数孕妇对IPTp-SP的使用具有中等至高水平的了解，但只有三分之一的孕妇确实服用了三剂或更多剂IPTp-SP。和有关IPTp-SP使用的高水平知识。在妊娠中期的300名孕妇中，有37名（12.3％）完全没有服用SP，而109名（36.3％），61名（20.3％）和93名（31％）分别服用了两剂，三剂，或分别使用更多SP剂量。尽管大多数孕妇对IPTp-SP的使用具有中等至高水平的了解，但只有三分之一的孕妇确实服用了三剂或更多剂IPTp-SP。